IMPROVE-IT: Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions

Sponsor
St. Joseph's Healthcare Hamilton (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04077281
Collaborator
Canadian Institutes of Health Research (CIHR) (Other)
300
2
10

Study Details

Study Description

Brief Summary

Medication safety is a crucial health issue for every older Canadian since many of the medications causing serious harm are those which also have life-saving or important symptom-relieving benefits. Very few specialists can accurately advise seniors which medications provide more benefit than harm for them personally, and make changes safely as this requires a very large breadth and depth of knowledge about the patient, the conditions they have and their therapies. Now that telemedicine is compatible with smart phones, this extends the ability of scarce specialists to 'see' any patient in Canada in a way that is more convenient for the patient and may be less expensive than current care. This project will find out whether a unique Clinical Pharmacology specialist team in Hamilton, Ontario can improve medication safety (stop medications no longer needed, reduce doses where appropriate, change to safer medications) for a high risk group of older hospitalized Canadians taking many medications. The hospital where this pilot study will take place was the first to install the world's leading electronic health record and set it up to facilitate and support high quality research. Patients who volunteer will be assigned to their usual care, or to the intervention which is the Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists. The investigators will study whether the intervention is effective and cost-effective at reducing harmful medication burden, reducing the need to return to hospital, or improving the patient's ratings of their care coordination. The results will determine whether a subsequent large trial is worthwhile.

Condition or Disease Intervention/Treatment Phase
  • Other: Medication Coordinated care
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Health Services Research
Official Title:
Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions (IMPROVE-IT): A Pilot Randomized Trial
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Arm

Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.

Other: Medication Coordinated care
Clinical Pharmacology & Toxicology consult CPT team completes detailed circle of care communication Telemedicine followup by CPT team (approximately 48 hrs post-discharge & 1 week to1 month post-discharge)

No Intervention: Control Arm (Usual care)

Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.

Outcome Measures

Primary Outcome Measures

  1. Feasibility Outcome: Recruitment rate for eligible patients. [Through the study completion, an average of 2 years]

    The main trial will be considered feasible if we are able to recruit at least 50% of eligible patients in this pilot.

  2. Clinical Outcome: The number of TRIIM-Meds successfully deprescribed. [2 months post discharge]

    The number of TRIIM-Meds successfully deprescribed (dose reduction or discontinued) at 2 months post-hospital discharge, aiming to be able to detect a mean difference of 0.5.

Secondary Outcome Measures

  1. Feasibility Outcomes of CPT consultation volume capacity and potential to apply the intervention entirely through telemedicine. [Through the study completion, an average of 2 years]

    This will be measured based on the number of successfully enrolled patients, and the number of patients that will entirely undergo the intervention through telemedicine.

  2. Feasibility Outcomes of patient retention rate. [Through the study completion, an average of 2 years]

    This will be measured by looking at the number of patients enrolled, the number of patients that dropped out, and the number of patients that completed the study.

  3. Feasibility Outcomes of likelihood of the intervention proving cost-effective. [Through the study completion, an average of 2 years]

    This will be measured using Healthcare resource utilization questionnaire, which will determine whether the intervention reduced healthcare costs compared to the control group.

  4. Patient-important outcomes: Participant ratings of coordination and continuity of transitions in care. [2 months post discharge]

    This outcome will be measured using the Coordination and Continuity of Care Questionnaire (CCCQ). Which is a questionnaire we adapted from the brief prepared questionnaire (B-PREPARED) and the three-question care transitions measure questionnaire (CTM-3).

  5. Patient-important outcomes: Health related quality of life: EQ-5D-5L [2 months post discharge]

    This outcome will be measured using the EuroQol five-dimensional, five-level descriptive system (EQ-5D-5L) that asks patients to self-assess their own health quality related quality of life. Whereas a scoring metric is used to assess the overall health related quality of life based on the answers to the questions. The questionnaire scale considers 1 as the best possible health and 5 as the worst health possible.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults over the age of 65 years.

  • Admitted to Medicine or Surgery services for more than 2 days.

  • High cost users (defined as):

  • Have at least one other hospitalization within the previous year.

  • Taking 5 or more chronic medications including at least one TRIIM-Med.

  • Provide informed consent.

Exclusion Criteria:
  • Patients with "do not approach status".

  • Patient or Caregiver not fluent in English.

  • Patients who do not provide informed consent.

  • Patients admitted for < 2 days.

  • Patients < 65 years of age.

  • Not a high cost user (as defined above).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • St. Joseph's Healthcare Hamilton
  • Canadian Institutes of Health Research (CIHR)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Anne Holbrook, Director, Division of Clinical Pharmacology & Toxicology Professor, Department of Medicine, McMaster University Medical Staff, Hamilton Health Sciences and St Joseph's Healthcare Hamilton, St. Joseph's Healthcare Hamilton
ClinicalTrials.gov Identifier:
NCT04077281
Other Study ID Numbers:
  • CIHR#419518
First Posted:
Sep 4, 2019
Last Update Posted:
Mar 16, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Anne Holbrook, Director, Division of Clinical Pharmacology & Toxicology Professor, Department of Medicine, McMaster University Medical Staff, Hamilton Health Sciences and St Joseph's Healthcare Hamilton, St. Joseph's Healthcare Hamilton
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2021